Sodium glucose co-transporter 2 (SGLT2) inhibitors have already remade the diabetes drug market. Now competition for new cardiac and renal indications is heating up among three of the main drugs in the class: Janssen’s Invokana (canagliflozin), AstraZeneca’s Farxiga (dapagliflozin), and Eli Lilly/Boehringer-Ingelheim’s Jardiance (empagliflozin).
Sodium glucose co-transporter 2 (SGLT2) inhibitors have already remade the diabetes drug market. Now competition for new cardiac and renal indications is heating up among three of the main drugs in the class: Janssen’s Invokana (canagliflozin), AstraZeneca’s Farxiga (dapagliflozin), and Eli Lilly/Boehringer-Ingelheim’s Jardiance (empagliflozin).
This is a high stakes contest. Heart failure costs the American health system more than $30 billion a year, and chronic kidney disease costs the Medicare program more than $84 billion.
Related: Diabetes Meds Go Beyond Blood Sugar Control
Invokana got off to an early start when the FDA approved it as a treatment for end-stage kidney disease a year ago. The drug got a bit of a boost last month when the FDA removed a boxed warning after newer data did not show an amputation risk.
Farxiga has gotten two important nods from the FDA this year. Earlier this month it was given a breakthrough therapy designation for chronic kidney disease based on results presented this summer at the European Society of Cardiology (ESC) meeting. In May, the FDA approved Farxiga as a treatment for paients with heart failure with reduced ejection fraction.
Jardiance was also in the limelight at ESC because investigators presented results showing that, like Farxiga, it seems to haveprotective cardiovascular effects in heart failure patients with low ejection fractions. Last month Jardiance received FDA’s fast track designation for treatment following a heart attack.
Lack of Diversity in Clinical Trials Hurts Research, and Costs Billions | AHA Scientific Sessions
November 12th 2023Healthcare researchers say it’s critical to get more women, Black and Latino participants in clinical trials. It can be done, but researchers and institutions must make the effort.
Read More
CMS Coverage Decision of Pulmonary Embolectomy Criticized
November 19th 2021JAMA Internal Medicine editor and a UCSF colleague wrote in a New England Journ of Medicine opinion piece that the decision highlights the need to establish a new requirement that would make coverage decisions contingent on evidence of benefit for Medicare population.
Read More
FDA Updates: Genentech Withdraws Tecentriq Indication; New Approvals for Xarelto, Tibsovo
August 28th 2021Tecentriq loses indication, Xarelto is approved for reduce risks of cardiovascular events, Tibsovo is approved for rare cancer, Skytrofa is a new, once-weekly growth hormone, and supplemental application is filed Orencia graft-versus-host disease.
Read More